International Group of Endovascular Oncology   Report issue

Academic/Hospital Phase 2
Founded: Pesaro Italy (2013)

Organization Overview

First Clinical Trial
2013
NCT02007148
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

capecitabine (xeloda) (1 trial)

docetaxel (taxotere) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2